| Popis: |
Guselkumab (Tremfya , Janssen Biotech, Inc., Horsham, PA, USA) is an anti-IL-23 p19 antibody, recently marketed for the management of moderate to severe psoriasis in adults. To date, there are only limited post-marketing data available on its effectiveness and tolerance. A retrospective, real-life multicenter study conducted in France and Belgium evaluated guselkumab tolerance and effectiveness at Month 4 (M4) in the treatment of cutaneous psoriasis, and to describe patient characteristics at baseline and after 4 months of treatment. Collected data included socio-demographic characteristics, psoriasis history (age at beginning, clinical type, associated psoriatic arthritis, previous treatments), comorbidities, psoriasis severity at beginning of treatment (PASI, PGA, DLQI) as well as about tolerance. A total of 194 patients were included; data was analyzed for 180 (14 were excluded due to missing PASI at inclusion or at M4). |
